MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
Assertio Holdings Total Shareholders Equity 2011-2026 | ASRT
Annual Total Shareholders Equity Assertio Holdings
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 138 M | 226 M | 102 M | 55.5 M | 58 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 226 M | 55.5 M | 116 M |
Quarterly Total Shareholders Equity Assertio Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 106 M | 93.3 M | 109 M | 121 M | 131 M | 132 M | 134 M | 138 M | 193 M | 254 M | 251 M | 226 M | 135 M | 128 M | 112 M | 102 M | 96.9 M | 92.3 M | 105 M | 55.5 M | 55.5 M | 55.5 M | 55.5 M | 58 M | 58 M | 58 M | 209 M | 220 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 254 M | 55.5 M | 124 M |
Total Shareholders Equity of other stocks in the Drug manufacturers industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
-17.3 M | - | - | $ 754 M |  USA |
 |
Alimera Sciences
ALIM
|
46.2 M | - | - | $ 142 M | USA |
 |
Canopy Growth Corporation
CGC
|
487 M | $ 1.08 | - | $ 116 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
8 M | - | 7.5 % | $ 6.35 M | USA |
 |
Evolus
EOLS
|
-23.1 M | $ 5.59 | - | $ 360 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-808 K | - | 0.86 % | $ 117 M | USA |
 |
Agile Therapeutics
AGRX
|
-16.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
Harrow Health
HROW
|
52.4 M | $ 39.22 | - | $ 1.44 B | USA |
 |
Catalent
CTLT
|
3.6 B | - | - | $ 11.5 B | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
73.8 M | - | - | $ 2.06 B |  France |
 |
China Pharma Holdings
CPHI
|
7.75 M | $ 0.58 | 5.64 % | $ 10.1 M |  China |
 |
DURECT Corporation
DRRX
|
14.8 M | - | - | $ 50.1 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
22.9 M | $ 3.67 | - | $ 51.6 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
234 M | - | -39.89 % | $ 27.7 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1.01 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Endo International plc
ENDP
|
-6.6 B | - | - | $ 28.9 M |  Irlanda |
 |
HEXO Corp.
HEXO
|
557 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Evoke Pharma
EVOK
|
-2.58 M | - | - | $ 36.6 M | USA |
 |
Organogenesis Holdings
ORGO
|
263 M | $ 2.87 | - | $ 378 M | USA |
 |
Aurora Cannabis
ACB
|
2.13 B | $ 3.65 | - | $ 86.3 M | Canada |
 |
Perrigo Company plc
PRGO
|
2.94 B | $ 11.69 | -0.04 % | $ 1.62 B | USA |
 |
Athenex
ATNX
|
-6.51 M | - | -23.39 % | $ 1.76 M | USA |
 |
Jupiter Wellness
JUPW
|
-2.17 M | - | - | $ 33.6 M | USA |
 |
Emergent BioSolutions
EBS
|
649 M | $ 8.77 | -0.11 % | $ 449 M | USA |
 |
Sundial Growers
SNDL
|
270 M | $ 1.54 | - | $ 3.37 M | Canada |
 |
Bausch Health Companies
BHC
|
-1.02 B | $ 5.63 | 0.09 % | $ 2.05 B | Canada |
 |
Lannett Company
LCI
|
-251 M | - | 1.15 % | $ 7.11 M | USA |
 |
TherapeuticsMD
TXMD
|
29.3 M | $ 2.16 | - | $ 22.6 M | USA |
 |
Veru
VERU
|
32.3 M | $ 2.51 | - | $ 339 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
186 M | - | - | $ 193 M | Canada |
 |
Viatris
VTRS
|
20.5 B | $ 14.71 | - | $ 17.7 B | USA |
 |
OrganiGram Holdings
OGI
|
300 M | $ 1.39 | - | $ 402 M | Canada |
 |
cbdMD
YCBD
|
1.96 M | $ 0.77 | -1.43 % | $ 3.32 M | USA |
 |
ProPhase Labs
PRPH
|
63.6 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-252 M | - | - | $ 1.42 B | USA |
 |
Rockwell Medical
RMTI
|
21.3 M | $ 0.89 | - | $ 20.8 M | USA |
 |
Pacira BioSciences
PCRX
|
778 M | $ 22.86 | - | $ 1.06 B | USA |
 |
PetIQ
PETQ
|
223 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
-86.6 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
35.7 M | - | -27.8 % | $ 2.56 M | USA |
 |
Recro Pharma
REPH
|
58.7 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
85.4 M | $ 4.77 | - | $ 144 M | USA |
 |
SCYNEXIS
SCYX
|
49.4 M | $ 0.78 | - | $ 38.9 M | USA |
 |
Solid Biosciences
SLDB
|
137 M | $ 6.14 | - | $ 251 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
4.41 M | $ 2.8 | 1.82 % | $ 3.47 M | USA |
 |
Tricida
TCDA
|
218 K | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
3.32 B | $ 7.3 | - | $ 4.51 B | Canada |
 |
Zynerba Pharmaceuticals
ZYNE
|
46.2 M | - | - | $ 55.5 M | USA |